Evaluation and Management of Patients with Cleft Lip/Palate and Microtia

Epidemiology and Key Clinical Features

• 22q11.2 deletion syndrome is the most common microdeletion disorder (prevalence ≈ 1 in 2,148 live births) and should be the first diagnostic consideration when cleft lip/palate and microtia coexist [1][2].
• Palatal abnormalities are present in roughly two‑thirds of individuals with 22q11.2 deletion syndrome, ranging from overt cleft palate to submucous cleft and velopharyngeal dysfunction [3][4].
• Auricular malformations are a recognized feature of 22q11.2 deletion syndrome; microtia, while less frequent, remains clinically relevant 5.
• Congenital heart defects affect about two‑thirds of affected patients, most often conotruncal anomalies such as tetralogy of Fallot, interrupted aortic arch type B, and truncus arteriosus [3][4].
• Additional distinguishing manifestations include immunodeficiency, hypocalcemia, developmental delay, cognitive deficits, learning disabilities, and characteristic facial dysmorphism (e.g., malar flattening, hooded eyelids, bulbous nasal tip, overfolded helices) [3][5].

Diagnostic Recommendations

• Chromosomal microarray analysis (CMA) is the recommended first‑line genetic test because it detects the 22q11.2 deletion and delineates its size and breakpoints [1][6].
• Fluorescence in situ hybridization (FISH) may be employed when CMA is unavailable, though it provides less comprehensive information [1][6].
• Parental testing is advised for every case to determine whether the deletion is de novo or inherited; approximately 10 % are inherited, and parents may exhibit mild phenotypic features 6.

Cardiac Evaluation

• Perform a comprehensive cardiac work‑up (echocardiogram + electrocardiogram) to identify conotruncal defects that occur in the majority of affected individuals [7][8].

Immunologic and Endocrine Assessment

• Screen for immunodeficiency using a complete blood count and T‑cell subset analysis 9.
• Evaluate serum calcium to detect hypocalcemia, a common metabolic abnormality in this syndrome [9][6].

Cleft‑Palate and Audiologic Assessment

• Refer to a cleft‑palate multidisciplinary team for detailed examination of palatal anatomy and velopharyngeal function [7][8].
• Conduct a formal audiologic evaluation because microtia and cleft palate confer a high risk of hearing impairment [7][8].

Multidisciplinary Management

• Assemble a multidisciplinary care team that includes genetics, cardiology, otolaryngology, audiology, speech‑language pathology, and cleft‑surgery specialists to address the complex needs of these patients [7][8].

Early Speech and Language Intervention

• Initiate speech and language assessment between 6 and 18 months of age, given the high prevalence of communication disorders in this population [3][4].

Peri‑operative Considerations

• Apply syndrome‑specific peri‑operative protocols that incorporate calcium monitoring and preparation for potential difficult airway management [9][6].

Long‑Term Surveillance

• Implement ongoing surveillance for cardiac complications, endocrine disturbances, neurodevelopmental delays, and emerging psychiatric conditions throughout the patient’s lifespan [3][7].

22q11.2 Deletion Syndrome and Cleft Palate: Epidemiology, Clinical Features, and Management

Epidemiology

• Approximately two‑thirds of individuals with any palatal abnormality (ranging from overt cleft palate to velopharyngeal dysfunction) have 22q11.2 deletion syndrome. 10
• In children with 22q11.2 deletion syndrome, palatal abnormalities are present in about 67 % of cases. 10

Palatal Phenotypes in 22q11.2 Deletion Syndrome

• Velopharyngeal dysfunction, with or without submucous cleft palate, is the most common palatal presentation, occurring in roughly two‑thirds of affected children. [10][11]
• Overt cleft palate is less frequent but still observed in a notable minority of patients. 10
• Cleft lip/palate (combined lip and palate involvement) is the least common palatal manifestation within this syndrome. 11

Associated Cardiac Anomalies

• Congenital heart defects are identified in approximately 67 % of individuals with 22q11.2 deletion syndrome, most commonly conotruncal lesions such as tetralogy of Fallot, interrupted aortic arch type B, and truncus arteriosus. 10

Metabolic and Endocrine Screening

• Routine metabolic screening for patients with 22q11.2 deletion syndrome should include assessment of calcium metabolism, parathyroid hormone, and thyroid function. 12

Speech‑Language Evaluation

• Formal speech‑language assessment is recommended to begin between 6 and 18 months of age for children with 22q11.2 deletion syndrome to detect velopharyngeal dysfunction early. 10

Perioperative Considerations for 22q11.2 Deletion Syndrome

• Airway management plans should anticipate potential difficulty, and preparation for a challenging airway is essential during surgical procedures. 10
• Patients are at increased risk for prolonged mechanical ventilation following surgery. 10

Multidisciplinary Care Team

• Genetic specialists should be involved in the evaluation and counseling of patients with 22q11.2 deletion syndrome. 12
• Cardiology care, preferably by a specialist in grown‑up congenital heart disease, is required for long‑term cardiac surveillance. 12
• Speech‑language pathology services are integral for ongoing assessment and therapy of speech and resonance problems. 10